Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Trial results show promising insights into the potential of retatrutide for addressing obesity and various weight-related conditions: In patients with type 2 diabetes (T2D) and obesity, subcutaneous administration of retatrutide for 12 weeks resulted in reductions in body weight of up to 8.96 kg with a safety and tolerability profile similar to other incretins (weight loss peptides)
The differential insulinotropic potency and other physiological effects of GIP and GLP-1 in both healthy individuals and those with T2DM may be linked to their distinct receptors and the downstream G proteins that transmit signals intracellularly
Consult Your Physician : Always consult with your healthcare provider before starting any compounded medication
Research Applications Gastrointestinal: Ulcer repair, gut lining integrity modelling, and IBD pathway research
US$ 27.92
US$ 27.36
US$ 29.52
US$ 21.50
